Brown University

Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting conceded that the mixed Phase III results for Biogen, Inc. / Eisai Co., Ltd. ’s Aduhelm (aducanumab) complicate decisions abo

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl

Biopharma’s inherent shortage of new product leads means that finding a good external research partner has become a strategic imperative. It’s a task made harder by the fact that the dance card of the

Global aging demographics along with increases in diabetes and obesity are providing a solid foundation for growth of the advanced wound care market. Hard-to-heal wounds, which encompass not only diab